Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy

Genetics in Medicine

Volumn 15, Issue 12, 2013, Pages 972-977

  Ingles, Jodie ^a,b   Sarina, Tanya ^a   Yeates, Laura ^a   Hunt, Lauren ^c   Macciocca, Ivan ^d,e   Mccormack, Louise ^c   Winship, Ingrid ^e   Mcgaughran, Julie ^c,f   Atherton, John ^c,f   Semsarian, Christopher ^a,b,g  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

genetic counseling; genetic testing; hypertrophic cardiomyopathy

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; FAMILY HISTORY; FEMALE; GENDER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC SCREENING; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEART VENTRICLE HYPERTROPHY; HETEROZYGOTE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUT OF HOSPITAL CARDIAC ARREST; OUTCOME ASSESSMENT; PREDICTION; SUDDEN CARDIAC DEATH;

ADULT; AGED; AUSTRALIA; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; GENETIC COUNSELING; GENETIC MARKERS; GENETIC TESTING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PEDIGREE; PHENOTYPE;

EID: 84886262225     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.44     Document Type: Article

References (29)

1. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell 2001;104:557-567
2. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: Clinical perspectives. J Am Coll Cardiol 2012;60:705-715
3. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:1064-1075
4. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92: 785-789
5. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011;8:1308-1339
6. Lind JM, Chiu C, Semsarian C. Genetic basis of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther 2006;4:927-934
7. Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc 2005;80:739-744
8. Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc 2005;80:463-469
9. Richard P, Charron P, Carrier L, et al.; EUROGENE Heart Failure Project. Hypertrophic cardiomyopathy: Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227-2232
10. Erdmann J, Daehmlow S, Wischke S, et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet 2003;64:339-349
11. Gray B, Ingles J, Semsarian C. Natural history of genotype positivephenotype negative patients with hypertrophic cardiomyopathy. Int J Cardiol 2011;152:258-259
12. Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. Am J Cardiol 2011;107:604-608
13. Ingles J, McGaughran J, Scuffham PA, Atherton J, Semsarian C. A costeffectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart 2012;98:625-630
14. Wordsworth S, Leal J, Blair E, et al. DNA testing for hypertrophic cardiomyopathy: A cost-effectiveness model. Eur Heart J 2010;31:926-935
15. Andersen PS, Havndrup O, Hougs L, et al. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. Hum Mutat 2009;30:363-370
16. Ingles J, McGaughran J, Vohra J, et al. Establishment of an Australian National Genetic Heart Disease Registry. Heart Lung Circ 2008;17:463-467
17. Gersh BJ, Maron BJ, Bonow RO, et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:e783-e831
18. Ingles J, Yeates L, Semsarian C. The emerging role of the cardiac genetic counselor. Heart Rhythm 2011;8:1958-1962
19. Ingles J, Zodgekar PR, Yeates L, Macciocca I, Semsarian C, Fatkin D; CSANZ Cardiac Genetic Diseases Council Writing Group. Guidelines for genetic testing of inherited cardiac disorders. Heart Lung Circ 2011;20:681-687
20. Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: Implications for genetic testing and counselling. J Med Genet 2005;42:e59
21. Chiu C, Bagnall RD, Ingles J, et al. Mutations in alpha-Actinin-2 cause hypertrophic cardiomyopathy: A genome-wide analysis. J Am Coll Cardiol 2010;55:1127-1135
22. Maron BJ, Semsarian C. Prevention of sudden death for patients with cardiomyopathies another step forward. J Am Coll Cardiol 2012;59: 501-502
23. Chiu C, Tebo M, Ingles J, et al. Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2007;43: 337-343
24. Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 2010;55:1444-1453
25. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108-1114
26. Semsarian C, Yu B, Ryce C, Lawrence C, Washington H, Trent RJ. Sudden cardiac death in familial hypertrophic cardiomyopathy: Are "benign" mutations really benigñPathology 1997;29:305-308
27. Saltzman AJ, Mancini-DiNardo D, Li C, et al. Short communication: The cardiac myosin binding protein C Arg502Trp mutation: A common cause of hypertrophic cardiomyopathy. Circ Res 2010;106:1549-1552
28. Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:1903-1910
29. Kelly M, Semsarian C. Multiple mutations in genetic cardiovascular disease: A marker of disease severity? Circ Cardiovasc Genet 2009;2:182-190